Biosimilars Naming Conventions On FTC Agenda – In More Ways Than One
This article was originally published in RPM Report
An planned Federal Trade Commission hearing on biosimilar competition will include discussion of the debate over the right approach to non-proprietary names. But FTC may be reopening another naming debate by referring to the hearing topic as “follow-on biologics.”
You may also be interested in...
Single Product, Single Price: Medicare Will Include All Versions Of Active Ingredient For Negotiation
The US Medicare agency intends to treat all dosage forms of the same active ingredient as a single drug for purposes of its new price negotiation authority. The approach will have implications for product branding and line extension strategies.
QALY Control: House Bill Would Ban Cost-Effectiveness Tool In US Programs
No one seems eager to defend the QALY tool as a House Republican bill seeks to prohibit any federal agency from using Quality Adjusted Life Years as a formula to determine pricing.
The ODAC Losing Streak Ends
US FDA’s Oncologic Drugs Advisory Committee’s endorsement of a first-line indication for Genentech’s Polivy is the first time the panel has voted ‘yes’ on a cancer drug application in almost three years.